Afinitor

(everolimus)

ApprovedSmall molecule

Everolimus is used to treat certain cancers (including kidney cancer and breast cancer) and to prevent organ rejection after transplant. It works by slowing down the growth of cancer cells and suppressing the immune system.[2] Afinitor is currently approved and in use across 164 indications[4].[1]

Afinitor is one of 2200 small molecule programs targeting Glioma. It is currently in Approved.

164

Indications

566

Total Trials

Active Trials

2,199

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

Coronary Artery DiseaseApproved

EpendymomaActive, not recruiting

Pancreatic NeoplasmActive, not recruiting

Hepatic FailureApproved

AstrocytomaActive, not recruiting

Non-Hodgkins LymphomaApproved

MetastasisActive, not recruiting

PTEN Hamartoma Tumor SyndromeApproved

Left Ventricular HypertrophyActive, not recruiting

GliomaPhase 2

Active, not recruiting

Coronary Artery DiseaseApproved

Approved

EpendymomaPhase 2

Active, not recruiting

Pancreatic NeoplasmApproved

Active, not recruiting

Hepatic FailureApproved

Approved

AstrocytomaApproved

Active, not recruiting

Non-Hodgkins LymphomaApproved

Approved

MetastasisPhase 1/Phase 2

Active, not recruiting

PTEN Hamartoma Tumor SyndromeApproved

Approved

Left Ventricular HypertrophyApproved

Active, not recruiting

Showing 10 of 163 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Afinitor

Novartis

Approved

67 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

Prolia

Amgen

Preclinical

14 4

Gemzar

GGynecologic Oncology Group

Preclinical

22 5

Zolymbus

AbbVie

Preclinical

1 6

Chantix

PPrism Pharmaceuticals

Preclinical

1 7

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 8

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 9

Lipegfilgrastim

Merck & Co.

Preclinical

1 10

Tianeptine

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Triple-Negative Breast Cancer

NCT05954442

Phase 1Active, not recruiting

Advanced Cancer

NCT01087554

Phase 3Active, not recruiting

Renal Cell Carcinoma

NCT04195750

Q4 2026

Phase 1Active, not recruiting

Dexamethasone

NCT03740334

Phase 2Not yet recruiting

Colorectal Cancer

NCT06301386

Phase 1Recruiting

Epilepsy

NCT07095933

Clinical

Trials by Indication[1]

Breast Cancer20 trials

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Active, not recruiting· Pfizer logo

Pfizer·Phase 2·NCT06105632·333 enrolled

Everolimus in Treating Patients WIth Recurrent or Metastatic Breast Cancer

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00255788·49 enrolled

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Completed· Novartis logo

Novartis·Phase 3·NCT00863655·724 enrolled

Show 17 more trials

Study of Combined Fulvestrant and Everolimus in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure

Completed·MMara Chambers·Phase 2·NCT00570921·33 enrolled

Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer

Completed·—·Phase 1/2·NCT00458237·11 enrolled

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 3·NCT05429684·120 enrolled

Trastuzumab With or Without Everolimus in Treating Women With Breast Cancer That Can Be Removed By Surgery

Terminated·UUNICANCER·Phase 2·NCT00674414·82 enrolled

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Recruiting·MMedSIR·Phase 3·NCT06382948·240 enrolled

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT01007942·569 enrolled

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Terminated·UUniversity of Maryland, Baltimore·Phase 2·NCT01499160·7 enrolled

A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer

Completed·QQueen Mary University of London·Phase 2·NCT02216786·333 enrolled

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Recruiting·—·Phase 2·NCT05983107·102 enrolled

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Completed· Novartis logo

Novartis·Phase 2·NCT03312738·159 enrolled

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Unknown status·CConsorzio Oncotech·Phase 3·NCT02404051·745 enrolled

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Unknown status·OOrganisation for Oncology and Translational Research·Phase 2·NCT02025712·35 enrolled

Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Completed· Novartis logo

Novartis·Phase 3·NCT00876395·719 enrolled

Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy

Active, not recruiting·UUNICANCER·Phase 3·NCT01805271·1,278 enrolled

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07062965·400 enrolled

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer

No longer available· Novartis logo

Novartis··NCT05108740

S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

Terminated·SSWOG Cancer Research Network·Phase 3·NCT02137837·37 enrolled

Renal Cell Carcinoma12 trials

Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

Terminated·SSandy Srinivas·Phase 2·NCT00651482·10 enrolled

A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

Completed· Eisai logo

Eisai·Phase 2·NCT02915783·41 enrolled

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

Completed· Eisai logo

Eisai·Phase 1·NCT02454478·7 enrolled

Show 9 more trials

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04195750·755 enrolled

CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

Unknown status·AAnewPharma·Phase 3·NCT03095040·390 enrolled

Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy

Completed· Roche logo

Roche·Phase 2·NCT01442090·85 enrolled

Terminated· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 4·NCT02338570·31 enrolled

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma

Completed·—·Phase 2·NCT01108445·131 enrolled

Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

Unknown status·FFudan University·Phase 2·NCT05124431·30 enrolled

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

Completed· Takeda logo

Takeda·Phase 2·NCT02724020·96 enrolled

Pilot Study of Neo-Adjuvant Everolimus to Treat Advanced Renal Cell Carcinoma - Analysis of Biomarkers

Completed·SSt. Joseph's Healthcare Hamilton·N/A·NCT01107509·20 enrolled

Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01217931·180 enrolled

Kidney Transplant10 trials

Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A

Completed·UUniversity Hospital, Bordeaux·Phase 4·NCT02328963·186 enrolled

Everolimus in de Novo Kidney Transplant Recipients

Completed· Novartis logo

Novartis·Phase 3·NCT01410448·383 enrolled

Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults

Unknown status·DDeise de Boni Monteiro de Carvalho·Phase 4·NCT01455649·30 enrolled

Show 7 more trials

Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.

Completed·UUniversity Hospital, Strasbourg, France·Phase 4·NCT03216967·130 enrolled

Treatment of Children With Kidney Transplants by Injection of CD4+CD25+FoxP3+ T Cells to Prevent Organ Rejection

Unknown status·PPirogov Russian National Research Medical University·Phase 1/2·NCT01446484·30 enrolled

Treg Therapy in Subclinical Inflammation in Kidney Transplantation

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT02711826·32 enrolled

Efficacy of a Quadruple Immunosuppressor Regimen With mTOR Inhibitors in Sensitized Kidney Transplant Patients

Recruiting·UUniversity of Sao Paulo General Hospital·Phase 4·NCT06584773·80 enrolled

MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney Transplantation

Unknown status·—·N/A·NCT02091973·50 enrolled

Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen

Completed· Novartis logo

Novartis·Phase 3·NCT00514514·802 enrolled

Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study

Completed· Chiesi Farmaceutici S.p.A. logo

Chiesi Farmaceutici S.p.A.·Phase 2·NCT02970630·28 enrolled

Liver Transplant6 trials

Liver Transplantation With Tregs at UCSF

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03654040·42 enrolled

Efficacy of Everolimus in Combination With Tacrolimus in Liver Transplant Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT01551212·339 enrolled

Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy

Completed· Novartis logo

Novartis·Phase 3·NCT00378014·276 enrolled

Show 3 more trials

De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study

Withdrawn·RRennes University Hospital·Phase 3·NCT02909335

EVR and EPO for Liver Transplant Tolerance

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06832189·20 enrolled

Expanding Liver Transplant Immunosuppression Minimization Via Everolimus

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06280950·340 enrolled

Renal Transplant Recipients5 trials

Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients

Withdrawn· Novartis logo

Novartis·Phase 4·NCT01269684

Study of Everolimus in de Novo Renal Transplant Recipients

Terminated·—·N/A·NCT01609673·1 enrolled

Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients

Completed· Novartis logo

Novartis·Phase 3·NCT01114529·828 enrolled

Show 2 more trials

Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT00634920·204 enrolled

Belatacept for Renal Transplant Recipients With Delayed Graft Function

Terminated·OOhio State University·Phase 1·NCT02134288·8 enrolled

104 more indications

Glioma5 trials

Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT03352427·3 enrolled

A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

Completed·SSt. Joseph's Hospital and Medical Center, Phoenix·Phase 1·NCT03834740·27 enrolled

Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas

Completed·—·Phase 2·NCT00782626·23 enrolled

Show 2 more trials

Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Recruiting·UUniversity of California, San Francisco·Phase 1·NCT04485559·50 enrolled

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

Completed·UUniversity of California, San Francisco·Phase 2·NCT01734512·65 enrolled

Kidney Cancer4 trials

S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Completed·SSWOG Cancer Research Network·Phase 3·NCT01120249·1,545 enrolled

Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00331409·23 enrolled

Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT01888042·61 enrolled

Show 1 more trial

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT01198158·77 enrolled

Efficacy and Safety4 trials

A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus

Unknown status·HHospital de Clinicas de Porto Alegre·Phase 4·NCT01608412·120 enrolled

Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

Completed· Novartis logo

Novartis·Phase 4·NCT00154310·300 enrolled

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

Active, not recruiting·IITM Solucin GmbH·Phase 3·NCT03049189·309 enrolled

Show 1 more trial

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

Completed· Novartis logo

Novartis·Phase 3·NCT00300274·721 enrolled

Prostate Cancer4 trials

Everolimus in Castrated Resistant Prostate Cancer(CRPC)Patients With PI3K-AKT-mTOR Signaling Pathway Deficiency

Unknown status·TTianjin Medical University Second Hospital·Phase 3·NCT03580239·120 enrolled

Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer

Completed·SSCRI Development Innovations, LLC·Phase 1·NCT02125084·38 enrolled

Everolimus as First-Line Therapy in Treating Patients With Prostate Cancer

Completed·SSwiss Cancer Institute·Phase 2·NCT00976755·37 enrolled

Show 1 more trial

ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02106507·9 enrolled

Lymphoma4 trials

Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00967044·31 enrolled

Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Completed·MMayo Clinic·Phase 2·NCT00436618·277 enrolled

Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Completed·MMayo Clinic·Phase 1/2·NCT01075321·58 enrolled

Show 1 more trial

Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma

Completed·MMassachusetts General Hospital·Phase 2·NCT00869999·26 enrolled

Postmenopausal Women3 trials

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Terminated·YYale University·Phase 2·NCT02236572·17 enrolled

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

Completed·JJules Bordet Institute·Phase 2·NCT02028364·55 enrolled

Resistance Training and Rapamycin to Enhance Bone Formation in Postmenopausal Women

Not yet recruiting·OOdense University Hospital·Phase 2·NCT07191353·148 enrolled

Metastatic Colorectal Cancer3 trials

Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer

Completed·HHerlev Hospital·Phase 2·NCT01387880·100 enrolled

Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus

Completed·HHerbert Hurwitz·Phase 2·NCT00597506·50 enrolled

Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer

Recruiting·OOslo University Hospital·Phase 2·NCT05725200·40 enrolled

Acute Myeloid Leukemia3 trials

Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 1·NCT01154439·11 enrolled

Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid Leukemia

Completed·TTechnical University of Munich·Phase 1/2·NCT00762632·40 enrolled

Everolimus, Cytarabine, and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Unknown status·IInstitut de Recherche Clinique sur les Cancers et le Sang·Phase 1·NCT00544999·21 enrolled

Advanced Solid Tumors3 trials

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Active, not recruiting· Amgen logo

Amgen·Phase 1·NCT04185883·610 enrolled

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT00954512·15 enrolled

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

Terminated·UUniversity of Cincinnati·Phase 1·NCT01508104·19 enrolled

Heart Transplant3 trials

Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant

Unknown status·FFundacion Investigacion y Desarrollo·Phase 4·NCT00695344·52 enrolled

SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance

Completed· Novartis logo

Novartis·Phase 4·NCT01266148·115 enrolled

Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up

Completed·RRabin Medical Center·Phase 4·NCT00596557·20 enrolled

Growth2 trials

Expanded Access Study of RAD001 in Metastatic Renal Cell Cancer Patients Who Are Intolerant of or Who Have Failed Despite Prior Vascular Endothelial Growth Factor Therapy

No longer available· Novartis logo

Novartis··NCT00655252

Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome

Withdrawn·JJochen Roessler·Phase 2·NCT02569125

Diffuse Large B-Cell Lymphoma2 trials

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

Completed· Novartis logo

Novartis·Phase 3·NCT00790036·742 enrolled

Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01334502·26 enrolled

Renal Transplantation2 trials

Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation

Unknown status·UUniversity Hospital, Antwerp·Phase 4·NCT00903188·152 enrolled

Renal Transplantation in the Elderly - nEverOld Study

Unknown status·UUniversity of Sao Paulo General Hospital·Phase 4·NCT01631058·90 enrolled

ART2 trials

Novartis Everolimus Transition

Completed·MMedical University of South Carolina·Phase 4·NCT02096107·60 enrolled

Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

Completed· Novartis logo

Novartis·Phase 4·NCT01789281·34 enrolled

Metastatic2 trials

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

Terminated·RRutgers, The State University of New Jersey·Phase 1/2·NCT00934895·27 enrolled

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe

Completed· Novartis logo

Novartis·Phase 2·NCT00688623·73 enrolled

Tuberous Sclerosis2 trials

Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex

Unknown status·EErasmus Medical Center·Phase 2/3·NCT01730209·60 enrolled

Topical Everolimus in Patients With Tuberous Sclerosis Complex

Withdrawn·HHospices Civils de Lyon·Phase 2/3·NCT02860494

Metastatic Prostate Cancer2 trials

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00085566·61 enrolled

Bicalutamide With or Without Everolimus in Treating Patients With Recurrent or Metastatic Prostate Cancer

Completed·UUniversity of California, Davis·Phase 2·NCT00814788·24 enrolled

Glioblastoma Multiforme2 trials

Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Terminated· Novartis logo

Novartis·Phase 2·NCT00515086·41 enrolled

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

Completed· Novartis logo

Novartis·Phase 1/2·NCT00107237·16 enrolled

Gastric Cancer2 trials

Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)

Completed· Novartis logo

Novartis·Phase 3·NCT00879333·656 enrolled

Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT00519324·54 enrolled

Renal Transplant2 trials

Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients

Completed· Novartis logo

Novartis·Phase 3·NCT00170833·80 enrolled

Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients

Completed· Novartis logo

Novartis·Phase 3·NCT00464399·20 enrolled

Mantle Cell Lymphoma2 trials

Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

Completed· Novartis logo

Novartis·Phase 2·NCT00702052·58 enrolled

Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy

Terminated·TTechnical University of Munich·Phase 2·NCT00727207·35 enrolled

Neuroendocrine Tumors2 trials

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Recruiting·GGrupo Espanol de Tumores Neuroendocrinos·Phase 3·NCT05918302·120 enrolled

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03070301·21 enrolled

Patients With Advanced Solid Tumors2 trials

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00423865·30 enrolled

Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

Completed·HHerbert Hurwitz, MD·Phase 1·NCT00276575·65 enrolled

Colorectal Cancer2 trials

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Not yet recruiting·FFudan University·Phase 2·NCT06301386·25 enrolled

Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer

Completed·TThe Queen Elizabeth Hospital·Phase 1/2·NCT01139138·49 enrolled

Pancreatic Neuroendocrine Tumor2 trials

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2/3·NCT07165886·243 enrolled

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Terminated·EEmory University·Phase 2·NCT02273752·2 enrolled

Advanced Solid Malignancies2 trials

Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.

Completed·AAmsterdam UMC, location VUmc·N/A·NCT01636908·43 enrolled

Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations

Completed·WWashington University School of Medicine·Phase 2·NCT02352844·12 enrolled

Efficacy1 trial

Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Terminated· Novartis logo

Novartis·Phase 2·NCT01374451·160 enrolled

Kidney1 trial

Shift to Everolimus (RAD) Kidney Sparing Study

Terminated·UUniversity of Bologna·Phase 4·NCT00420537·34 enrolled

Cardiac Transplant1 trial

Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy

Completed· Novartis logo

Novartis·Phase 3·NCT00097968

Seizure1 trial

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Active, not recruiting· Novartis logo

Novartis·Phase 3·NCT02962414·206 enrolled

Testicular Germ Cell Cancer1 trial

Everolimus in Refractory Testicular Germ Cell Cancer

Completed·NNational Cancer Institute, Slovakia·Phase 2·NCT01466231·15 enrolled

Gynecologic Cancer1 trial

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Completed·FFox Chase Cancer Center·Phase 1·NCT01281514·21 enrolled

Cutaneous T-cell lymphoma1 trial

Everolimus in Treating Cutaneous T-cell Lymphoma

Terminated·AAdam Lerner·Phase 2·NCT01637090·3 enrolled

Circulating Tumor Cells1 trial

Circulating Tumor Cells and Tumor DNA in HCC and NET

Completed·UUniversity of Aarhus··NCT02973204·167 enrolled

Metastatic Head and Neck Cancer1 trial

Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer

Terminated·UUniversity College, London·Phase 1/2·NCT01313390·4 enrolled

Renal Allograft Recipients1 trial

Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients

Unknown status·SSeoul St. Mary's Hospital·Phase 4·NCT02036554·234 enrolled

Chronic Myelogenous Leukemia1 trial

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

Completed· Novartis logo

Novartis·Phase 1/2·NCT00093639

Liver Metastases1 trial

Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT01678664·74 enrolled

Lymphangioleiomyomatosis1 trial

A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis

Completed· Novartis logo

Novartis·Phase 2·NCT01059318·24 enrolled

Complication1 trial

PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood

Completed·GGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH·Phase 2·NCT01509560·21 enrolled

Clear Cell Renal Cancer1 trial

Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer

Terminated·AAssociació per a la Recerca Oncologica, Spain·Phase 2·NCT01784978·41 enrolled

Chronic Lymphocytic Leukemia1 trial

Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·MMayo Clinic·Phase 1/2·NCT00935792·28 enrolled

Malignancies1 trial

Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast

Completed·—·Phase 1·NCT03154281·14 enrolled

Metastatic Melanoma1 trial

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01014351·70 enrolled

Acute Coronary Syndrome1 trial

Controlled Level EVERolimus in Acute Coronary Syndromes

Completed·UUniversity of Zurich·Phase 1/2·NCT01529554·150 enrolled

Thyroid Cancer1 trial

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT02143726·35 enrolled

Urothelial Carcinoma1 trial

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Terminated·MMatthew Galsky·Phase 2·NCT01215136·36 enrolled

Gallbladder Carcinoma1 trial

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT02836847·152 enrolled

Arteriosclerosis1 trial

Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation

Terminated·DDianet Dialysis Centers·Phase 4·NCT01276834·13 enrolled

Patient Preference1 trial

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

Completed·IiOMEDICO AG·Phase 4·NCT02248571·85 enrolled

Autosomal Dominant Polycystic Kidney Disease1 trial

Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease

Completed· Novartis logo

Novartis·Phase 4·NCT00414440·431 enrolled

Multiple Myeloma1 trial

Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT00618345·35 enrolled

Non-Small Cell Lung Cancer1 trial

Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer

Unknown status·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT01167530·36 enrolled

Primary Peritoneal Cavity Cancer1 trial

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Completed·MMayo Clinic·Phase 2·NCT02283658·20 enrolled

Trial1 trial

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Terminated·OOHSU Knight Cancer Institute·Phase 1·NCT03878524·2 enrolled

Resistance1 trial

Rotating Pazopanib and Everolimus to Avoid Resistance

Completed·NNetherlands Working Group on Immunotherapy of Oncology·Phase 2·NCT01408004·101 enrolled

Withdrawal1 trial

Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.

Completed· Novartis logo

Novartis·Phase 3·NCT01023815·330 enrolled

Gemcitabine1 trial

Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine

Completed· Novartis logo

Novartis·Phase 1/2·NCT00560963·21 enrolled

Intracranial Meningioma1 trial

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

Terminated·SSCRI Development Innovations, LLC·Phase 2·NCT00972335·18 enrolled

Left Ventricular Hypertrophy1 trial

Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study

Unknown status·IInstituto de Urologia e Nefrologia·Phase 4·NCT02493465·50 enrolled

Toxicity1 trial

Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation

Terminated·WWashington University School of Medicine·Phase 4·NCT02974686·1 enrolled

Cancer Metastatic1 trial

Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls

Unknown status·SSinai Hospital of Baltimore·N/A·NCT02450175·50 enrolled

Liver Cancer1 trial

Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

Terminated·SSwiss Cancer Institute·Phase 1/2·NCT01009801·27 enrolled

ADPKD1 trial

Everolimus on CKD Progression in ADPKD Patients

Terminated·—·Phase 2/3·NCT01009957·71 enrolled

Advanced Malignancy1 trial

Everolimus and Capecitabine in Patients With Advanced Malignancy

Unknown status·—·Phase 1/2·NCT01079702·35 enrolled

HER21 trial

Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02152943·37 enrolled

Endometrial Carcinoma1 trial

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01797523·62 enrolled

Lung Transplantation1 trial

Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation

Completed· Novartis logo

Novartis·Phase 4·NCT00377962·282 enrolled

Triple-Negative Breast Cancer1 trial

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype

Recruiting·FFudan University·Phase 3·NCT05954442·203 enrolled

Temozolomide1 trial

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Recruiting·NNationwide Children's Hospital·Phase 2·NCT05843253·120 enrolled

Relapsed or Refractory1 trial

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Unknown status·SSamsung Medical Center·Phase 2·NCT02638428·90 enrolled

Recurrent Colon Cancer1 trial

Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer

Completed·FFox Chase Cancer Center·Phase 1·NCT01637194·12 enrolled

Advanced1 trial

Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT01567488·43 enrolled

Macroglobulinemia1 trial

Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

Terminated·—·Phase 1/2·NCT01125293·46 enrolled

ESS1 trial

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane

Terminated·GGBG Forschungs GmbH·Phase 3·NCT01773460·3 enrolled

Serous Carcinoma1 trial

Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation

Completed·—·Phase 2/3·NCT03285802·1 enrolled

Transplant Recipient1 trial

Everolimus in de Novo Heart Transplant Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT01017029·182 enrolled

Leukemia1 trial

Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/Lymphoma

Completed·EEmory University·Phase 1·NCT03328104·8 enrolled

Unresectable Solid Tumor1 trial

Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy

Completed·MMayo Clinic·Phase 1·NCT00949949·38 enrolled

Birt-Hogg-Dube syndrome1 trial

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02504892·3 enrolled

Unresectable1 trial

Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases

Completed·EEmory University·Phase 1·NCT01469572·13 enrolled

Malignant Peripheral Nerve Sheath Tumor1 trial

SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT01661283·25 enrolled

Dexamethasone1 trial

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Active, not recruiting·—·Phase 1·NCT03740334·45 enrolled

Completed·UUMC Utrecht·N/A·NCT01566279·73 enrolled

Soft Tissue Sarcoma1 trial

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas

Unknown status·SSidnei Epelman·Phase 2·NCT01216839·20 enrolled

Esophageal Cancer1 trial

Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer

Completed·—·Phase 1/2·NCT01231399·6 enrolled

Tumor1 trial

MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01827384·208 enrolled

Osteosarcoma1 trial

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma

Unknown status·SSidnei Epelman·Phase 2·NCT01216826·20 enrolled

Lenalidomide1 trial

Study of Everolimus (RAD001) in Combination With Lenalidomide

Completed·EEmory University·Phase 1·NCT01218555·44 enrolled

Epilepsy1 trial

The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy

Recruiting·XXuanwu Hospital, Beijing·Phase 1·NCT07095933·5 enrolled

Sturge-Weber syndrome1 trial

Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)

Withdrawn·—·Phase 2·NCT01997255

Neuroendocrine Carcinoma1 trial

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01204476·27 enrolled

Metastatic Cancer1 trial

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT01298713·111 enrolled

Stent Implantation1 trial

Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation

Unknown status·GGerman Heart Institute·Phase 3·NCT00426049·484 enrolled

Advanced Urothelial Cancer1 trial

Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer

Completed·—·Phase 1·NCT01184326·23 enrolled

Advanced Cancer1 trial

Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT01087554·249 enrolled

Induction Chemotherapy1 trial

Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL

Completed·—·Phase 1·NCT01523977·22 enrolled

Central Nervous System Tumor1 trial

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Completed· Eisai logo

Eisai·Phase 1/2·NCT03245151·64 enrolled

Esophageal Adenocarcinoma1 trial

LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02138929·25 enrolled

Renal Cancer1 trial

A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer

Terminated·QQueen Mary University of London·Phase 2·NCT01793636·49 enrolled

Endometrial Cancer1 trial

Everolimus in Treating Patients With Relapsed or Metastatic Endometrial Cancer

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT00870337·44 enrolled

Unspecified2 trials

IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus

Withdrawn·MMilton S. Hershey Medical Center·Phase 2·NCT01234974

SCHEDULE Follow Up Visit 5-7 yr

Completed· Novartis logo

Novartis·Phase 4·NCT02864706·95 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 20, 2010

ZORTRESS

NDA NDA021560

Jul 9, 2010

AFINITOR

NDA NDA022334

Aug 29, 2012

AFINITOR DISPERZ

NDA NDA203985

Sources

References

[1]
ClinicalTrials.gov — 566 trial records for everolimus. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Afinitor drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — everolimus compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for everolimus. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA203985). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Afinitor. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: FK506-Binding Protein 1a Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Patent Landscape[6]

Patent Cliff

Jul 1, 2028

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8410131Nov 1, 2025

8410131*PEDMay 1, 2026

9006224Jul 1, 2028